Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Verastem, Inc.NASDAQ: VSTM

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 83.7%

Gross margin was 83.7% in Q1 FY2026. On a trailing-twelve-month basis it was 83.7%, down 16.3 pp year over year. Over 3 fiscal years it narrowed by 17.1 pp.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
83.7%+0.1 pp QoQ
Last fiscal yearDec 2025
82.9%-17.1 pp YoY
LTMMar 2026
83.7%-16.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-17.1 pp——
3 years-17.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
82.9%
Year-over-year change
-17.1pp

Gross Margin vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 gross margin of 83.7% is the 5th highest of the 7 companies compared; the peer median is 94.4%.
  • Its year-over-year change of -16.3 pp is the 4th highest of 6, against a peer median of -2.3 pp.
  • Over three fiscal years its change of -17.1 pp compares with a peer median of -10.8 pp.
VSTM Competitors Peer median
Gross Margin for VSTM and competitors
Company Period LTM level YoY 3-year change
ANLAdlai Nortye Ltd.LTM Jun 2024100.0% ——
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
NUVBNuvation Bio Inc.LTM Jun 202693.9% +66.4 pp—
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
ORICORIC Pharmaceuticals, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
BBOTBridgeBio Oncology Therapeutics Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding VSTM) 94.4%-2.3 pp-10.8 pp

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.